CAMP4 Therapeutics Corporation Research and Development Expense
CAMP4 Therapeutics Corporation (CAMP) reported Research and Development Expense of $10.82 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- CAMP4 Therapeutics Corporation research and development expense for the quarter ending 2026-06-30 was $10.82M, a 4.58% increase year-over-year.
- CAMP4 Therapeutics Corporation research and development expense for the quarter ending 2026-03-31 was $10.16M, a 0.14% increase year-over-year.
- CAMP4 Therapeutics Corporation research and development expense for the quarter ending 2025-12-31 was $8.36M, a 16.40% decline year-over-year.
- CAMP4 Therapeutics Corporation research and development expense for the quarter ending 2025-09-30 was $9.36M, a 3.57% decline year-over-year.
- CAMP4 Therapeutics Corporation research and development expense for fiscal 2025 was $38.20M, a 1.58% decline from fiscal 2024.
- CAMP4 Therapeutics Corporation research and development expense for fiscal 2024 was $38.82M, a 4.43% decline from fiscal 2023.
- CAMP4 Therapeutics Corporation research and development expense for fiscal 2023 was $40.62M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.82M 10-Q · filed 2026-08-13 | $20.98M 10-Q · filed 2026-08-13 | $29.33M derived: sum of 3 quarters · filed 2026-08-13 | $38.69M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $10.16M 10-Q · filed 2026-05-07 | $18.52M derived: sum of 2 quarters · filed 2026-05-07 | $27.87M derived: sum of 3 quarters · filed 2026-05-07 | $38.22M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $8.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $17.71M derived: sum of 2 quarters · filed 2026-03-05 | $28.06M derived: sum of 3 quarters · filed 2026-08-13 | $38.20M 10-K · filed 2026-03-05 |
| 2025-09-30 | $9.36M 10-Q · filed 2025-11-06 | $19.70M derived: sum of 2 quarters · filed 2026-08-13 | $29.84M 10-Q · filed 2025-11-06 | $39.84M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $10.34M 10-Q · filed 2026-08-13 | $20.49M 10-Q · filed 2026-08-13 | $30.48M derived: sum of 3 quarters · filed 2026-08-13 | $40.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $10.15M 10-Q · filed 2026-05-07 | $20.14M derived: sum of 2 quarters · filed 2026-05-07 | $29.84M derived: sum of 3 quarters · filed 2026-05-07 | $39.23M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $19.70M derived: sum of 2 quarters · filed 2026-03-05 | $29.09M derived: sum of 3 quarters · filed 2026-03-05 | $38.82M 10-K · filed 2026-03-05 |
| 2024-09-30 | $9.70M 10-Q · filed 2025-11-06 | $19.09M derived: sum of 2 quarters · filed 2025-11-06 | $28.82M 10-Q · filed 2025-11-06 | $39.49M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $9.39M 10-Q · filed 2025-08-14 | $19.13M 10-Q · filed 2025-08-14 | $29.79M derived: sum of 3 quarters · filed 2025-08-14 | $39.61M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $9.74M 10-Q · filed 2025-05-13 | $20.40M derived: sum of 2 quarters · filed 2025-05-13 | $30.22M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $10.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $20.48M derived: sum of 2 quarters · filed 2025-03-27 | $40.62M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $9.82M 10-Q · filed 2024-11-21 | $29.95M 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |